NCT06761911Not yet recruitingPhase 4
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
A Real-world Study of Brentuximab Vedotin Monotherapy and Combination Regimens in the Treatment of Relapsed/Refractory Hodgkin Lymphoma
Source: ClinicalTrials.gov · Last updated 7 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are: To evaluate the efficacy and toxicity of BV-containing regimen in relapsed/refractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 12 Nov 2024
- Start date
- 31 Dec 2024
- Primary completion date
- 17 Dec 2025
- Lead sponsor
- Xiuhua Sun
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT06761911
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 31 Dec 2024 to the primary completion date, 17 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- \<18 years
Who the study is looking for
- Histologically, classical hodgkin lymphoma（cHL） was diagnosed and relapsed or refractory.
- Patients were treated with BV-containing regimen at least once
- Presence of tumor (measurable or nonmeasurable).
- Signature of the form consent for participation in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.